Advertisement

Management of Thyroid Cancer

  • M. P. Rowland
  • A. J. Waghorn
  • S. Vinjamuri
Chapter
Part of the Clinicians’ Guides to Radionuclide Hybrid Imaging book series (CGRHI)

Abstract

Please check if identified heading levels are correct.

References

  1. 1.
    Perros P, Boelaert K, Colley S, et al. Guidelines for the management of thyroid cancer. Clin Endocrinol (Oxf). 2014;81:–1, 122.Google Scholar
  2. 2.
    Department of Health. (2006) Cancer Waiting Times: A Guide (Version 5). London: DH. www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/DH_06306761.Google Scholar
  3. 3.
    Hambly NM, Gonen M, Gerst SR. Implementation of Evidence-based guidelines for thyroid nodule biopsy: a model for establishment of practice standards. Am J Roentgenol. 2011;196:655–60.CrossRefGoogle Scholar
  4. 4.
    Perros P, Boelaert K, Colley S, et al. Guidelines for the management of thyroid cancer—Chapter 4 Ultrasound assessment of thyroid nodules. Clin Endocrinol (Oxf). 2014;81:14–8.CrossRefGoogle Scholar
  5. 5.
    Perros P, Boelaert K, Colley S, et al. Guidelines for the management of thyroid cancer—Chapter 5 Fine-Needle aspiration cytology. Clin Endocrinol (Oxf). 2014;81:19–20.CrossRefGoogle Scholar
  6. 6.
    Perros P, Boelaert K, Colley S, et al. Guidelines for the management of thyroid cancer—Chapter 3 Presentation, diagnosis and referral. Clin Endocrinol (Oxf). 2014;81:10–1.CrossRefGoogle Scholar
  7. 7.
    Perros P, Boelaert K, Colley S, et al. Guidelines for the management of thyroid cancer—Chapter 7.5 Diagnostic thyroid surgery. Clin Endocrinol (Oxf). 2014;81:26.CrossRefGoogle Scholar
  8. 8.
    Seningen JL, Nassar A, Henry MR. Correlation of thyroid nodule fine-needle aspiration cytology with corresponding histology at Mayo Clinic, 2001-2007: an institutional experience of 1,945 cases. Diagn Cytopathol. 2012;40(Suppl. 1):E27–32.CrossRefPubMedGoogle Scholar
  9. 9.
    Perros P, Boelaert K, Colley S, et al. Guidelines for the management of thyroid cancer—Chapter 7.6 Therapeutic surgery for thyroid cancer. Clin Endocrinol (Oxf). 2014;81:27.CrossRefGoogle Scholar
  10. 10.
    Hart DM, Leboulleux S, Al Ghuzlan A, et al. Optimization of staging of the neck with prophylactic central and lateral neck dissection for papillary thyroid carcinoma. Ann Surg. 2012;255:777–83.CrossRefGoogle Scholar
  11. 11.
    Lang BH, Wong KP, Wan KY, et al. Impact of routine unilateral central neck dissection on preablative and postablative stimulated thyroglobulin levels after total thyroidectomy in papillary thyroid carcinoma. Ann Surg Oncol. 2012;19:60–7.CrossRefPubMedGoogle Scholar
  12. 12.
    Perros P, Boelaert K, Colley S, et al. Guidelines for the management of thyroid cancer—Chapter 8.3Management of papillary microcarcinoma. Clin Endocrinol (Oxf). 2014;81:33.CrossRefGoogle Scholar
  13. 13.
    Lang W, Choritz H, Hundeshagen H. Risk factors in follicular thyroid carcinomas. A retrospective follow-up study covering a 14-year period with emphasis on morphological findings. Am J Surg Pathol. 1986;10:246–55.CrossRefPubMedGoogle Scholar
  14. 14.
    Nagar S, Aschebrook-Kilfoy B, Kaplan EL, et al. Hurthle cell carcinoma: an update on survival over the last 35 years. Surgery. 2013;154:1263–71.CrossRefPubMedGoogle Scholar
  15. 15.
    Perros P, Boelaert K, Colley S, et al. Guidelines for the management of thyroid cancer—Chapter 7.6 Therapeutic surgery for thyroid cancer. Clin Endocrinol (Oxf). 2014;81:28.CrossRefGoogle Scholar
  16. 16.
    Kushchayeva Y, Duh QY, Kebebew E, et al. Comparison of clinical characteristics at diagnosis and during follow-up in 118 patients with Hurthle cell or follicular thyroid cancer. Am J Surg. 2008;195:457–62.CrossRefPubMedGoogle Scholar
  17. 17.
    Perros P, Boelaert K, Colley S, et al. Guidelines for the management of thyroid cancer—Chapter 7.8 Therapeutic surgery for thyroid cancer. Clin Endocrinol (Oxf). 2014;81:29.CrossRefGoogle Scholar
  18. 18.
    Baek SK, Jung KY, Kang SM, et al. Clinical risk factors associated with cervical lymph node recurrence in papillary thyroid carcinoma. Thyroid. 2010;20:147–52.CrossRefPubMedGoogle Scholar
  19. 19.
    Ito Y, Kudo T, Kobayashi K, et al. Prognostic factors for recurrence of papillary thyroid carcinoma in the lymph nodes, lung, and bone: analysis of 5,768 patients with average 10-year follow-up. World J Surg. 2012;36:1274–8.CrossRefPubMedGoogle Scholar
  20. 20.
    Farrag T, Lin F, Brownlee N, et al. Is routine dissection of level II-B and V-A necessary in patients with papillary thyroid cancer undergoing lateral neck dissection for FNA-confirmed metastases in other levels. World J Surg. 2009;33:1680–3.CrossRefPubMedGoogle Scholar
  21. 21.
    Perros P, Boelaert K, Colley S, et al. Guidelines for the management of thyroid cancer—Chapter 9 Radioiodine remnant ablation and therapy for differentiated thyroid cancer. Clin Endocrinol (Oxf). 2014;81:37.CrossRefGoogle Scholar
  22. 22.
    Perros P, Boelaert K, Colley S, et al. Guidelines for the management of thyroid cancer—Chapter 9 Radioiodine remnant ablation and therapy for differentiated thyroid cancer. Clin Endocrinol (Oxf). 2014;81:38.CrossRefGoogle Scholar
  23. 23.
    Perros P, Boelaert K, Colley S, et al. Guidelines for the management of thyroid cancer—Chapter 9.7 Radioiodine remnant ablation and therapy for differentiated thyroid cancer. Clin Endocrinol (Oxf). 2014;81:42.CrossRefGoogle Scholar
  24. 24.
    Perros P, Boelaert K, Colley S, et al. Guidelines for the management of thyroid cancer—Chapter 10.1. External beam radiotherapy for differentiated thyroid cancer. Clin Endocrinol (Oxf). 2014;81:46.CrossRefGoogle Scholar
  25. 25.
    Perros P, Boelaert K, Colley S, et al. Guidelines for the management of thyroid cancer—Chapter 17. Medullary thyroid cancer. Clin Endocrinol (Oxf). 2014;81:69.CrossRefGoogle Scholar
  26. 26.
    Perros P, Boelaert K, Colley S, et al. Guidelines for the management of thyroid cancer—Chapter 17.3. Medullary thyroid cancer. Clin Endocrinol (Oxf). 2014;81:70.CrossRefGoogle Scholar
  27. 27.
    Fife KM, Bower M, Harmer C. Medullary thyroid cancer: the role of radiotherapy in local control. Eur J Surg Oncol. 1996;22:588–91.CrossRefPubMedGoogle Scholar
  28. 28.
    Iten F, Müller B, Schindler C, et al. Response to [90Yttrium-DOTA]-TOC treatment is associated with long-term survival benefit in metastasized medullary thyroid cancer: a phase II clinical trial. Clin Cancer Res. 2007;13(Pt 1):6696–702.CrossRefPubMedGoogle Scholar
  29. 29.
    Kraeber-Bodéré F, Rousseau C, Bodet-Milin C, et al. Targeting, toxicity, and efficacy of 2-step, pretargeted radioimmunotherapy using a chimeric bispecific antibody and 131I-labeled bivalent hapten in a phase I optimization clinical trial. J Nucl Med. 2006;47:247–55.PubMedGoogle Scholar
  30. 30.
    Perros P, Boelaert K, Colley S, et al. Guidelines for the management of thyroid cancer—Chapter 18. Anaplastic thyroid cancer. Clin Endocrinol (Oxf). 2014;81:79–80.CrossRefGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Department of SurgeryRoyal Liverpool University HospitalLiverpoolUK
  2. 2.Department of Nuclear MedicineRoyal Liverpool and Broadgreen University Hospitals NHS TrustLiverpoolUK

Personalised recommendations